We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+10.19%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$125B
AUM Growth
+$7.74B
(+6.6%)
Cap. Flow
-$1.18B
Cap. Flow
% of AUM
-0.95%
Top 10 Holdings %
Top 10 Hldgs %
32.47%
Holding
4,267
New
79
Increased
1,134
Reduced
2,614
Closed
100
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Applovin
APP
|
+$80.1M |
| 2 |
Chevron
CVX
|
+$75.4M |
| 3 |
Robinhood
HOOD
|
+$52.2M |
| 4 |
Nutanix
NTNX
|
+$32.2M |
| 5 |
Datadog
DDOG
|
+$29.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$166M |
| 2 |
Apple
AAPL
|
+$150M |
| 3 |
NVIDIA
NVDA
|
+$148M |
| 4 |
HES
Hess
HES
|
+$72.3M |
| 5 |
ANSS
Ansys
ANSS
|
+$59M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.89% |
| 2 | Financials | 13.4% |
| 3 | Consumer Discretionary | 10.96% |
| 4 | Communication Services | 9.45% |
| 5 | Healthcare | 9.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1726
AtriCure
ATRC
$2.11B
| $2.75M | ﹤0.01% |
78,141
-2,306
| -3% | -$79.5K |
|
1727
Intellia Therapeutics
NTLA
$1.67B
| $2.75M | ﹤0.01% |
159,479
-4,767
| -3% | -$58.7K |
|
1728
Helix Energy Solutions
HLX
$1.41B
| $2.75M | ﹤0.01% |
418,612
-7,467
| -2% | -$47K |
|
1729
Vita Coco
COCO
$3.6B
| $2.74M | ﹤0.01% |
64,594
+1,532
| +2% | +$56.8K |
|
1730
BigBear.ai
BBAI
$1.57B
| $2.74M | ﹤0.01% |
420,614
-6,231
| -1% | -$39.9K |
|
1731
Stock Yards Bancorp
SYBT
$2.6B
| $2.74M | ﹤0.01% |
39,134
-2,912
| -7% | -$225K |
|
1732
Apogee Enterprises
APOG
$908M
| $2.74M | ﹤0.01% |
62,816
-583
| -0.9% | -$25K |
|
1733
Phibro Animal Health
PAHC
$1.39B
| $2.74M | ﹤0.01% |
67,609
-3,715
| -5% | -$123K |
|
1734
Helios Technologies
HLIO
$2.76B
| $2.73M | ﹤0.01% |
52,390
-969
| -2% | -$45.2K |
|
1735
Dave Inc
DAVE
$4.06B
| $2.73M | ﹤0.01% |
13,696
-385
| -3% | -$83.1K |
|
1736
FIVE9
FIVN
$2.54B
| $2.73M | ﹤0.01% |
112,780
-3,850
| -3% | -$102K |
|
1737
Procept Biorobotics
PRCT
$1.17B
| $2.69M | ﹤0.01% |
75,475
-1,909
| -2% | -$87.2K |
|
1738
Blue Bird Corp
BLBD
$2.18B
| $2.68M | ﹤0.01% |
46,612
-1,667
| -3% | -$87K |
|
1739
Twist Bioscience
TWST
$7.25B
| $2.68M | ﹤0.01% |
95,207
-4,154
| -4% | -$126K |
|
1740
KB Financial Group
KB
$43.5B
| $2.67M | ﹤0.01% |
32,249
-5,562
| -15% | -$456K |
|
1741
WIX.com
WIX
$2.52B
| $2.67M | ﹤0.01% |
15,043
-857
| -5% | -$129K |
|
1742
Celldex Therapeutics
CLDX
$3.28B
| $2.67M | ﹤0.01% |
103,157
-3,442
| -3% | -$79.8K |
|
|
LIF
1743
Life360
LIF
$5.12B
| $2.66M | ﹤0.01% |
25,017
+562
| +2% | +$47.3K |
|
|
APLS
1744
DELISTED
Apellis Pharmaceuticals
APLS
| $2.66M | ﹤0.01% |
117,429
-4,573
| -4% | -$107K |
|
1745
Unilever
UL
$136B
| $2.65M | ﹤0.01% |
39,699
-7,166
| -15% | -$495K |
|
1746
Globalstar
GSAT
$10.8B
| $2.64M | ﹤0.01% |
72,519
-1,939
| -3% | -$55.6K |
|
|
FBRT
1747
Franklin BSP Realty Trust
FBRT
$657M
| $2.63M | ﹤0.01% |
242,382
+4,217
| +2% | +$46.5K |
|
1748
Shinhan Financial Group
SHG
$35.6B
| $2.62M | ﹤0.01% |
51,962
-5,228
| -9% | -$256K |
|
|
HAPN
1749
Happen Inc
HAPN
$2.24B
| $2.62M | ﹤0.01% |
172,207
-3,015
| -2% | -$45.7K |
|
1750
Garrett Motion
GTX
$5.57B
| $2.62M | ﹤0.01% |
192,017
+3,248
| +2% | +$41.1K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2025 Portfolio in Review
As of Q3 2025, RhumbLine Advisers held 4,267 positions worth $125B, up 6.6% from $117B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Trading was light in Q3 2025: portfolio turnover was 4.2%. RhumbLine Advisers opened 79 new positions and exited 100, leaving the 4,267-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 32% a quarter earlier, followed by Financials and Consumer Discretionary.
- RhumbLine Advisers's largest Q3 2025 buy was The Marzetti Company: 64,390 shares worth $11.1M.
- RhumbLine Advisers added most to Applovin in Q3 2025, an estimated $80.1M increase.
- RhumbLine Advisers's biggest Q3 2025 reduction was Microsoft, cutting an estimated $166M.
- RhumbLine Advisers fully exited Hess in Q3 2025, selling an estimated $72.3M.
- RhumbLine Advisers's ten largest holdings make up 32% of its $125B portfolio in Q3 2025.
- RhumbLine Advisers opened 79 new positions and closed 100 in Q3 2025.
- RhumbLine Advisers's portfolio value rose 6.6% quarter-over-quarter to $125B.
Based on RhumbLine Advisers's 13F filing for Q3 2025, filed 6 Nov 2025.